

Prevalence of malaria among women attending a tertiary hospital in Sokoto metropolis, North-Western Nigeria

Gabriel N. Uyaiabasi^{1,2}, Millicent L. Umaru³

¹Department of Pharmacology, Benjamin S. Carson (Snr) School of Medicine, Babcock University, Ilishan – Remo, Ogun Nigeria.

²Department of Pharmacology, Therapeutics and Toxicology, College of Medicine, University of Lagos Idi – Araba, Lagos Nigeria.

³Department of Pharmacology & Toxicology, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

Corresponding author: Millicent L. Umaru

Email: xonyowo@gmail.com; Phone: +2348037014269

ABSTRACT

Background: Nigeria currently has the second largest maternal mortality and highest transmission of malaria in the world. Approximately 9.2 million women and young girls who get pregnant annually in Nigeria are at risk of malaria in pregnancy (MIP). MIP is associated with adverse outcomes on both the mother and foetus.

Objective: To assess the prevalence of malaria among women attending a tertiary hospital within Sokoto metropolis.

Methods: The study was cross-sectional retrospective study. Records of women aged 15 years and above were extracted from the patient records (Jan – Dec, 2015) at Specialist Hospital Sokoto. Statistical analysis was performed using Chi-Squared test and risk ratio was calculated.

Result: A total of 71,384 women attended the hospital during the study period of which 10,408 were diagnosed to have malaria giving a prevalence of 14.6%. The prevalence was higher ($p < 0.05$) among pregnant women, MIP (18.0%) than non-pregnant women, MIW (13.7%). The highest prevalence was recorded in the month of January (30.9%) while the lowest prevalence was seen in December with a prevalence of 8.2%.

Conclusion: The prevalence of malaria in the study population was 14% and pregnant women had a higher risk of malaria infection. A more robust prospective study is required to confirm the findings.

Key words: Maternal health, Malaria, Malaria in pregnancy, maternal death, prevalence, women.

Prévalence du paludisme chez les femmes fréquentant un hôpital tertiaire dans la métropole de Sokoto , nord-ouest du Nigéria

Gabriel N. Uyaiabasi^{1,2}, Millicent L. Umaru³

¹Département de pharmacologie, École de médecine Benjamin S. Carson (Snr), Université Babcock, Ilishan - Remo, Ogun, Nigeria.

²Département de pharmacologie, de thérapeutique et de toxicologie, Collège de médecine, Université de Lagos Idi - Araba, Lagos Nigeria.

³Département de pharmacologie et de toxicologie, Faculté des sciences pharmaceutiques,, Université Usmanu Danfodiyo, Sokoto, Nigeria.

Correspondance: Millicent L. Umaru

Email: xonyowo@gmail.com; Téléphone : +2348037014269

RÉSUMÉ

Contexte: Le Nigéria occupe actuellement la deuxième position en mortalité maternelle et la première en transmission du paludisme au monde. Au Nigéria, environ 9,2 million de femmes et de jeunes filles enceintes chaque année risquent de contracter le paludisme pendant la grossesse (PPG). Le PPG est associée à des effets indésirables sur la mère et le fœtus.

Objectif: Evaluer la prévalence du paludisme chez les femmes fréquentant un hôpital tertiaire dans la métropole de Sokoto.

Méthodes: L'étude était une étude rétrospective transversale. Les dossiers des femmes âgées de 15 ans et plus ont été extraits des dossiers des patients (janvier - décembre 2015) à Specialist Hospital (hôpital spécialisé) Sokoto. L'analyse statistique a été effectuée en utilisant le test du chi carré et le rapport de risque a été calculé.

Résultat : un total de 71 384 femmes ont fréquenté l'hôpital pendant la période d'étude dont 10 408 cas de paludisme ont été diagnostiqués, soit une prévalence de 14,6%. La prévalence était plus élevée ($p < 0,05$) chez les femmes enceintes, PPG (18,0%) que chez les femmes non enceintes, le paludisme chez les femmes (13,7%). La prévalence la plus élevée a été enregistrée au mois de janvier (30,9%) tandis que la prévalence la plus faible a été observée en décembre avec une prévalence de 8,2%.

Conclusion: La prévalence du paludisme dans la population étudiée était de 14% et les femmes enceintes avaient un risque plus élevé d'infection palustre. Une étude prospective plus robuste est nécessaire pour confirmer les résultats.

Mots-clés: Santé maternelle, Paludisme, Paludisme pendant la grossesse, décès maternel, prévalence, femmes.

INTRODUCTION

Nigeria joined the committee of nations to sign the United Nations Millennium Development Goals (MDGs) declaration in year 2000, with a commitment to reduce extreme poverty, improve access to quality healthcare, reduce maternal and child deaths, eradication or significant reduction in infectious diseases such as HIV/AIDS, malaria etc.¹ Over 15 years after this declaration, laudable maternal health metrics seem to be elusive to Nigeria.² Nigeria currently has the second highest maternal mortality in the world. In Nigeria, a woman's chance of dying from pregnancy or complications due to child birth is 1 in 13, compared to 1 in 31 for sub-Saharan Africa as a whole.^{3,4} Some of the most vulnerable maternal populations in the country include the poor, uneducated, adolescents, multiparous women, women in rural areas or Northern Nigeria.³

Malaria is still a major health problem in Nigeria and it accounts for the majority of hospital visitations and admissions in all age groups including pregnant women.⁵ There are over 140 million people at risk of malaria every year in Nigeria and about 50% of the adult population experience more than one bout of malaria in a year.⁵ Nigeria currently has the highest infection and transmission rates of malaria in the world and accounted for about 29% of all reported cases in 2013.⁶ Malaria in pregnancy (MIP), peripheral or placental infection by *Plasmodium*,^{7,9} is a major public health issue because of its adverse outcomes on mother and foetus. Pregnant women in low to high transmission areas of malaria are increasingly susceptible to MIP. MIP may sometimes remain asymptomatic; however it can greatly increase the risk of maternal anaemia, low birth weight, miscarriage, stillbirth and infant mortality.⁷⁻¹⁰ The disease is responsible for 11% of maternal mortality in the country, 30% of childhood deaths and still poses a significant health threat to all age groups.^{5,11} Therefore, the World Health Organization (WHO) recommends administration of at least two doses of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment (IPTp) to pregnant women leaving in malaria endemic areas during their antenatal clinic (ANC) visits.¹¹⁻¹³

Malaria is holoendemic in Nigeria.^{14,15} Although several studies on malaria prevalence has been carried-out,¹⁶⁻²³ these studies are usually state or region specific and cannot adequately represent the prevalence of the

disease nationwide because of social - cultural peculiarities of the various ethnic groups, environmental and other climatic conditions which varies widely across the country.¹⁹ Various prevalence values have been reported for MIP across the country. For instance, in a cross-sectional study of 659 pregnant women at a secondary health facility in Abuja, North-Central of Nigeria, the prevalence of MIP was found to be 38.8%.¹⁸ In addition, prevalence of 7.7%²⁰ and 4.8%²¹ were reported in Lagos, South-West and Sokoto, North-West, Nigeria, respectively. In a control study conducted in Midwestern Nigeria in 2009, results showed a significant reduction in both peripheral and placental parasitaemia in group of women who took two or three doses of IPTp-SP (16.2%) versus the group who didn't receive any treatment (23.7%).²³ There was also a significant reduction in the adverse event associated with MIP such as anaemia, risks of abortion, preterm delivery, and low birth weight in the treated group vs the untreated group.²³

The prevalence of MIP is influenced by several factors such as transmission intensity, pre-immunity, parity of the mother and use of protective measures such as insecticide-treated nets (ITNs) and IPTp.^{22, 24-26} Women in their first and second pregnancies are usually more prone to malaria.^{10, 27-28} It is estimated that approximately 50 million women living in malaria endemic areas become pregnant annually⁸ indicating that large number of women are at risk of the infection yearly.

The gains made towards malaria control are once again being threatened following the reports of emergence of resistance to artemisinin-based combination therapies (ACTs) in Southeast Asia.^{6, 29, 30} In addition, there are emerging reports of reduced IPTp efficacy due to SP resistance.^{31,32} The development of SP resistance will undoubtedly have an untoward influence on the malaria burden. For instance, in East Africa resistance to IPTp has been associated with an increased risk of foetal anaemia and severe malaria in the infants.³² With the reports of rising resistance to SP, it is important to monitor the prevalence of the MIP, an important determinant of maternal health indices. Hence this study was design to ascertain the prevalence of malaria among women attending the outpatient clinics of the Specialist Hospital Sokoto, from January to December 2015.

METHOD

Study location

The study was conducted at Specialist Hospital Sokoto a tertiary healthcare facility in the Metropolitan city of Sokoto, Sokoto State. Specialist Hospital has one of the highest patient attendances in the State because of the cost of Medicare is highly subsidized by the State Government. Sokoto State is located in the extreme Northwest of Nigeria, with an annual average temperature of 28.3°C. For most of the year, Sokoto is very hot and can also have extreme cold temperatures during the cold season.³³ There are two major seasons, wet (June-September) and dry (October-May). The two seasons are distinct and are characterized by high and low malarial transmission respectively.³⁴ The population of Sokoto metropolis is about 581,300³⁵ and approximately 147,046 are women between the ages 15-64 years.³⁵ Malaria is hyperendemic with seasonal variations. Like most parts of Nigeria, *P. falciparum* is the dominant *Plasmodium* species in the state.³⁵

Study design and data collection

This study was a cross-sectional retrospective study using records (sex, age, pregnancy status, diagnosis etc.) of patients seen at Outpatient Department and Ante-natal Clinics from January to December 2015. The inclusion criteria included women who were 15 years and above, attending either the Female Outpatient or Ante Natal clinics within the study period and having

relevant bio data. The data were verified and duly signed by both the Data Officer Hospital Activities Analysis Unit and the Head, Medical Records department. Ethical approval for the study was obtained from Ethical Review Committee of the Specialist Hospital Sokoto.

Statistical analysis

The means and percentages were calculated using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA), Chi-Square tests and relative risks were performed using IBM® SPSS® Statistics v20.0. International Business Machine Corp. The significance level was set at $p < 0.05$.

RESULTS

A total of 71,384 women attended the out patients clinics during the study period. Among these 15,095 were pregnant and attending the ANC clinic, while 56,289 were not pregnant. A total of 10,408 were diagnosed to have malaria giving a prevalence of 14.6%. The prevalence was higher ($p < 0.05$) among pregnant women, MIP (18.0%, 2719/15095) than non-pregnant women, MIW (13.7%, 7689/56289). In both groups, a higher number of cases were seen in women aged 15-45 years compared to 46 years & above (73.2% vs 26.8% for MIW, $p < 0.05$; 75.6% vs 24.4% for MIP, $p < 0.05$). The highest prevalence was recorded in the month of January (30.9%) while the lowest prevalence was seen in December with a prevalence of 8.2% ($p < 0.05$) [Table 1]. The age-group distribution of MIP and MIW is shown in Figure 1.

Table 1: Monthly-distribution of Prevalence of Malaria among Women Attending the Out-Patient Clinics of Specialist Hospital Sokoto between January and December, 2015

Month	Number of Patients	Patients with Malaria	Prevalence (%)
January	1061	328	30.9
February	2766	752	27.2
March	4454	868	19.5
April	5450	838	15.4
May	4889	853	17.4
June	3615	647	17.9
July	4984	689	13.8
August	7900	1109	14.0
September	7437	1042	14.0
October	8468	1256	14.8
November	7207	954	13.2
December	13153	1072	8.2

The average monthly malaria positive cases were 867 ± 71.5 (SEM). Table 2 presents the relative risk and prevalence of malaria among the women. The

prevalence was higher among pregnant women ($p < 0.05$) and aged 15-45 years ($p = 0.021$).




Fig. 1: Prevalence Malaria in Women Based on Age and Pregnancy Status
(MIW – malaria in women not pregnant; MIP – Malaria in Pregnancy)

Table 2 Relative risks of malaria in pregnant women and women between 15-45 years.

Variable	Total Number of Women	Number with Malaria (%)	Relative Risks (95% CI)
<u>Pregnancy Status</u>			
Yes	15,095	2,719 ^α (18.0)	1.319 (1.267 - 1.372)
No	56,289	7,689 (13.7)	0.950 (0.942 - 0.957)
<u>Age (years)</u>			
15 – 45	52,039	7684 ^β (14.8)	1.049 (1.007 - 1.092)
46 - Above	19,345	2,724 (14.1)	0.992 (0.985 - 0.999)

^αstatistically significant using *Pearson Chi - Square* ($p < 0.05$)

^βstatistically significant using *Pearson Chi - Square* ($p = 0.021$)

DISCUSSION

Malaria is still a major health concern in Nigeria and it is also a major influencer of the maternal health in the country. Malaria in pregnancy contributes significantly to the maternal health metrics in terms of morbidity and mortality. An average of 867 women was diagnosed with malaria every month in this study and was higher than enrolments in other studies within the country and the study duration was longer.^{20, 36} The prevalence of malaria among the patients attending the hospital was 14.6% and is within the range of earlier reported figures,^{21, 23} but much lower than the 38% reported by Ogbu *et al.*¹⁸ This study showed that malaria is still the major reason for hospital visitations within the country. The highest prevalence was seen in the month of January. This is a deviation from the norm, because the highest prevalence for malaria is usually reported during the malaria transmission season of August to December. A study done within the same period however did not report month specific prevalence¹⁷ and therefore direct comparison could not be made. The prevalence of MIP were seen more in women aged 15 – 45 years, and this is in line with previous reported findings.^{10, 20-23, 28}

The prevalence of malaria among pregnant women attending the ANC clinic for the study period was 18.0%. This figure is lower than the 59.9% reported by Nwagba and colleagues for Enugu within a study period of 18 months¹⁷ and the 38.8% prevalence reported for a tertiary hospital in Abuja Nigeria.¹⁸ A two-month study conducted by Isah and colleagues amongst pregnant women attending ANC in Usmanu Danfodiyo Teaching

hospital (UDUTH) in Sokoto reported MIP prevalence of 3.1% using direct microscopy and 4.8% with the Rapid Diagnostic Test.²¹ The reason for the observed difference could have been due to difference in infection pattern of malaria in study areas, study duration and possibly use of other malaria preventive measure. However, the lack of well-coordinated and consistent studies on MIP within the country makes it very difficult to ascertain the actual prevalence of MIP in Nigeria.

The recent reports of emerging resistance to SP,^{31, 38-40} which is the only chemoprophylaxis agent used presently as IPTp in pregnant women is a major source of concern, considering that the country has the highest infective and transmission rates of malaria in the world.^{5, 6, 12} A large population of women and young girls are still exposed to malaria, which further increases MIP associated adverse events to the foetus, neonates' susceptibility to congenital malaria and also portends a serious health risk to mothers and infants.

For Sustainable Development Goals to be achieved in Nigeria by 2030, there must be deliberate and positive changes in the area of data generation, collection and monitoring of important health indices such as malaria, maternal health, infant and maternal mortality. Such data must also be evidence based and readily verifiable, as this is the only way the health system management can be effective.^{2, 3} This study, although preliminary in nature, showcased the prevalence of malaria among women in Sokoto metropolis.

A major drawback of this study was that, the method for malaria diagnosis was not clearly stated and most of the diagnoses for malaria were based on clinical presentations, this would have led to misdiagnosis and overtreatment. Therefore efforts should be made to increase and improve diagnosis using parasitological screening. Earlier study in Sokoto in another tertiary facility reported 62.2% based on clinical symptomatology and 37.8% laboratory confirmed diagnosis.³⁷ Other limitations of this study include the gestational age and gravidity of malaria infected pregnant women were not recorded, and whether or not the women were given the IPTp – SP as at when due were not properly documented. This will have assisted to better classify the MIP seen among the women, because multigravidas (women who have been pregnant two or more times) usually have a form of protective immunity when compared to primigravidas (women with their first pregnancy).^{7-9, 23} There was also no record of the number of women who had access to other preventive measures such as the use of insecticide treated nets. Pregnant women who sleep under ITNs or use other malaria preventive methods

have been known to have lower incidence of malaria.^{13,23}

CONCLUSION

Malaria was identified as an important reason for hospital visitations among women in Sokoto metropolis. The risk of having malaria was higher in pregnant women compared to those who were not and more cases were seen in women aged 15 – 45 years which is consistent with previous reported studies. A more robust study is required within this vicinity in order to identify the probable causative factors and possible ways to ameliorate the situation and improve the maternal health indices of women in the state.

ACKNOWLEDGEMENT

The authors are grateful to the office of the Chairman Medical Advisory Committee of the Specialist Hospital Sokoto, the Head and the staff of the Medical Records Department and officers of the Hospital Activity Unit for their support. The authors also appreciate the efforts of Mallam Abubakar Gagi, Mustapha Isah and Hajia Hadiza Lawal for their assistance in collecting the data.

REFERENCES

1. United Nations Millennium Project. Who they are. [Retrieved 2017 Aug 17] available from <http://www.unmillenniumproject.org/goals>.
2. Oleribe OO, Taylor-Robinson SD (2016). Before Sustainable Development Goals (SDG): why Nigeria failed to achieve the Millennium Development Goals (MDGs). *Pan African Medical Journal* 24: 156.
3. Izugbara CO, Wekesah FM, Adedini SA (2016). Maternal Health in Nigeria: A Situation Update. *African Population and Health Research Center (APHRC)*, Nairobi, Kenya.
4. World Health Organization (2015). Trends in maternal mortality: 1990 to 2015. Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva: *World Health Organization*.
5. Federal Ministry of Health (2011). National Policy on Malaria Diagnosis and Treatment. Federal Ministry of Health National Malaria and Vector Control Division Abuja-Nigeria.
6. WHO, World Health Organisation (2014). World Malaria Report 2015. Geneva, *World Health Organization*.
7. Okpere EE, Enabudoso EJ, Osemwenkha AP (2010). Malaria in Pregnancy. *Nigerian Medical Journal* 51: 109-113.
8. Moya-Alvarez V, Abellana R, Cot M (2014). Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. *Malaria Journal* 13: 271.
9. De Beaudrap P, Turyakira, E, Nabasumba C, Tumwebaze B, Piola P, Boum II Y, McGready R (2016). Timing of malaria in pregnancy and impact on infant growth and morbidity: a cohort study in Uganda. *Malaria journal* 15(1): 92.
10. Balogun ST, Adeyanju OA, Adedeji AA, Fehintola FA, (2011). Predictors of asymptomatic malaria in pregnancy. *Nigerian Journal of Physiological Sciences* 26: 179 – 183.
11. Federal Ministry of Health [Nigeria] and National Malaria Elimination Programme (2014). *National Malaria Strategic Plan 2014-2020*. Abuja, Nigeria.
12. Ter Kuile FO, van Eijk AM, Filler SJ (2007). Resistance on the efficacy of intermittent preventive therapy. *JAMA* 297(23): 2603-16.
13. WHO, World Health Organisation (2015). Guidelines for the treatment of malaria 3rd (ed). Geneva, *World Health Organization*.
14. Federal Ministry of Health (2011). National Policy on Malaria Diagnosis and Treatment. *Federal Ministry of Health National Malaria and Vector Control Division Abuja-Nigeria*.

15. Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, *et al.* (2014). Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children. *The American Journal of Tropical Medicine and Hygiene* 91(5): 25–35.
16. Aina OO, Agomo CO, Olukosi Y, Okoh HI, Iwalokun B, Egbuna KN (2013). Malariometric survey of Ibeshe community in Ikorodu, Lagos state: Dry season. *Malaria Research and Treatment* 487250: 1–7.
17. Nwagha UI, Ugwu VO, Nwagha TU, Anyaehie BU (2009). Asymptomatic Plasmodium parasitemia in pregnant Nigerian women: Almost a decade after Roll Back Malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 103:16–20.
18. Ogbu GI, Aimakhu CO, AjenAnzaku S, Ngwan S and Ogbu DA (2015). Prevalence of malaria parasitaemia among asymptomatic women at booking visit in a tertiary hospital, Northcentral Nigeria. *Journal of Reproductive Biology and Health*, 3: 1.
19. Umaru ML, Uyaiabasi GN (2015). Prevalence of Malaria in Patients Attending the General Hospital Makarfi, Makarfi Kaduna – State, North Western Nigeria. *American Journal of Infectious Diseases and Microbiology* 3(1): 1-5.
20. Agomo CO, Oyibo WA, Anorlu RI, Agomo PU (2009). Prevalence of malaria in pregnant women in Lagos, South-West Nigeria. *Korean Journal of Parasitology* 47(2): 179–83.
21. Isah AY, Amanabo MA, Ekele BA (2011). Prevalence of malaria parasitemia amongst asymptomatic pregnant women attending a Nigerian teaching hospital. *Annals of African Medicine* 10: 1714
22. Balogun ST, Fehintola FA, Adeyanju OA, Adedeji AA (2010). Asexual and sexual stages of *Plasmodium falciparum* in Nigerian pregnant women attending antenatal booking clinic. *Obstetric Medicine* 3(3): 106–109.
23. Aziken ME, Akubuo KK, Gharoro EP, (2011). Efficacy of intermittent preventive treatment with sulfadoxine–pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. *International Journal of Gynecology and Obstetrics* 112: 30–33.
24. Desai M, Kuile FO, Nosten F, McGready R, Asamo K, Brabin B, Newman RD (2007). Epidemiology and burden of malaria in pregnancy. *Lancet Infectious Diseases* 7(2): 93–104.
25. Adeola AA, Okwilagwe EA (2015). Acceptance and Utilisation of Sulphadoxine-Pyrimethamine and Insecticide-Treated Nets among Pregnant Women in Oyo State, Nigeria. *Malaria Research and Treatment* 713987: 1–9.
26. Fehintola FA, Balogun ST, Adeoye SB (2012). Intermittent Preventive Treatment during Pregnancy with Sulphadoxine-Pyrimethamine May Promote *Plasmodium falciparum* Gametocytogenesis. *Medical Principles and Practice* 21: 63–67.
27. Bouyou-Akotet MK, Issifou S, Meye JF, Kombila M, Ngou-Milama E, Luty AJ, *et al.* (2004). Depressed natural killer cell cytotoxicity against *Plasmodium falciparum* infected erythrocytes during first pregnancies. *Clinical Infectious Diseases* 38: 3427.
28. Igunma Y, Ande A, Ezeanochie M, Hayes K (2010). Malaria in Pregnancy: Experience with Intermittent Preventive Treatment in A University Teaching Hospital in Southern Nigeria. *Benin Journal of Postgraduate Medicine* 12(1): 14-19.
29. Noedl H, Schaecher K, Smith BL, Socheat D and Fukuda MM (2008). Evidence of artemisinin-resistant malaria in western Cambodia. *New England Journal of Medicine* 359: 2619–2620.
30. Rogers JS, Wijesinghe SR and Meshnick RS (2010). Host immunity as a determinant of treatment outcome in *Plasmodium falciparum* malaria. *Lancet Infectious Diseases* 10: 51–59.
31. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, Eng JV, Owino SO, Lal AA, OmosunYO, Otieno K, Desai M, ter Kuile FO, Nahlen B, Moore J, Hamel MJ, Ouma P, Slutsker L, Shi YP (2012). Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in *Plasmodium falciparum* parasites from pregnant women in western Kenya. *Malaria Journal* 11: 134.
32. Baraka V, Ishengoma DS, Fransis F, MinjaDTR, Madebe RA, Ngatunga D, Van Geertruyden J (2015). High-level *Plasmodium falciparum* sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. *Malaria Journal* 14:439.
33. Aghedo FI, Shehu RA, Umar RA, Jiya MN, Erhabor O (2013). Antioxidant vitamin levels among preschool children with uncomplicated *Plasmodium falciparum* malaria in Sokoto, Nigeria. *Journal of Multidisciplinary Healthcare* 6: 259–63.

34. Erhabor O, Mohammad HJ, Onuigue FU, Abdulrahman Y and Ezimah AC (2014). Anaemia and Thrombocytopenia among Malaria Parasitized Children in Sokoto, North Western Nigeria. *Journal of Hematology & Transfusion* 2(2): 1020.
35. C o u r t e s y <https://www.citypopulation.de/php/nigeria-admin.php>. [Retrieved February 13, 2018].
36. Agomo CO, Oyibo WA, Odukoya-Maije F (2011). Parasitologic assessment of two-dose and monthly intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine. *Malaria Research and Treatment* 932895.
37. Jimoh AO, Shehu CE, Panti AA, Sani Z, Abubakar K, Danzaki AM (2013). Antimalarial use in the management of malaria in pregnancy in a tertiary care setting in Sokoto, north western Nigeria. *Caliphate Medical Journal* 1: 2-3.
38. Tahita MC, Tinto H, Erhart A, Kazienga A, Fitzhenry R, Van Overmeir C, Rosanas-Urgell A, Ouedraogo B, Guiguemde RT, Van Geertruyden J, D'Alessandro U (2015). Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. *PLoS One* 10(9): e0137440.
39. Baraka V, Ishengoma DS, Fransis F, Minja DTR, Madebe RA, Ngatunga D, Van Geertruyden J (2015). High-level *Plasmodium falciparum* sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. *Malaria Journal* 14: 439.
40. Oguike MC, Falade CO, Shu E, Enato IG, Watila I, Baba ES, et al., (2016). Molecular determinants of sulfadoxine-pyrimethamine resistance in *Plasmodium falciparum* in Nigeria and the regional emergence of dhps 431V. *International Journal for Parasitology: Drugs and Drug Resistance* 6(3): 220–229.